SCHEMBL6319205

SCHEMBL6319205

CN[C@H](Cc1ccc2ccccc2c1)C(=O)N(C)[C@H](Cc1ccccc1)C(=O)NCC1CC1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.49
GHSR Q92847 2/20 0.44
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
FCER2 P06734 2/20 0.43
TACR1 P25103 4/20 0.42
F10 P00742 2/20 0.42
PRSS1 P07477 2/20 0.42
MME P08473 1/20 0.42
ACE P12821 1/20 0.42
CPA1 P15085 1/20 0.42
ACE2 Q9BYF1 1/20 0.42
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
YAP1 P46937 1/20 0.41
CAPN1 P07384 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8715806 0.87 FCER2 (0.52) GHSRMMP9MMP8FCER2MME
SCHEMBL6324655 0.87 MME (0.47) GHSRMMP9MMP8FCER2MME
SCHEMBL8906161 0.87 CYP1A2 (0.45)
SCHEMBL6319439 0.87 CYP1A2 (0.45)
SCHEMBL6316765 0.87 BDKRB2 (0.45) GHSRMMP9MMP8FCER2TACR1
SCHEMBL6317992 0.86 FCER2 (0.53) GHSRMMP9MMP8FCER2TACR1
SCHEMBL4427112 0.86 FCER2 (0.53) GHSRMMP9MMP8FCER2TACR1
SCHEMBL4426088 0.86 FCER2 (0.53) GHSRMMP9MMP8FCER2TACR1
SCHEMBL6320195 0.85 FCER2 (0.46) GHSRMMP9MMP8FCER2MME
SCHEMBL8580483 0.85 FCER2 (0.46) GHSRMMP9MMP8FCER2MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 NPY5R 60/4885GHSR 2/4885MMP9 2831/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR NPY5R 56/4885GHSR 2/4885MMP9 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.